Edwards Lifesciences price target raised to $175 from $153 at RBC Capital

RBC Capital analyst Glenn Novarro raised his price target on Edwards Lifesciences to $175 and kept his Outperform rating after its Analyst Day presentation. The analyst notes that the 2019 revenue growth guidance of 11%-15% “demonstrates the sustainability of double-digit growth in transcatheter aortic valve replacement business despite increased competition and pricing/reimbursement headwinds.”
https://thefly.com/landingPageNews.php?id=2832921